Technical Analysis for IBRX - ImmunityBio, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 7.92 | -4.12% | -0.34 |
Earnings due: May 9
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Calm After Storm | Range Contraction | -4.12% | |
| NR7 | Range Contraction | -4.12% | |
| Inside Day | Range Contraction | -4.12% | |
| Wide Bands | Range Expansion | -4.12% | |
| Gapped Up | Strength | -4.12% | |
| Upper Bollinger Band Walk | Strength | 1.41% |
| Alert | Time |
|---|---|
| Possible NR7 | about 3 hours ago |
| 60 Minute Opening Range Breakdown | about 4 hours ago |
| Down 5% | about 8 hours ago |
| Down 3% | about 8 hours ago |
| Fell Below Previous Day's Low | about 8 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/09/2024
ImmunityBio, Inc. Description
NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer of clinical dose forms of off-the-shelf natural killer (NK) cell therapies. The activated NK cell platform is designed to destroy cancer and virally-infected cells. The safety of these optimized, activated NK cells-as well as their activity against a broad range of cancers-has been tested in phase I clinical trials in Canada and Europe, as well as in multiple phase I and II clinical trials in the United States. By leveraging an integrated and extensive genomics and transcriptomics discovery and development engine, together with a pipeline of multiple, clinical-stage, immuno-oncology programs, NantKwest's goal is to transform medicine by bringing novel NK cell-based therapies to routine clinical care. NantKwest is a member of the NantWorks ecosystem of companies.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Immune System Immunotherapy Infectious Diseases Cancer Treatment Cancer Immunotherapy Genomics Virotherapy Natural Killer Cell Lymphocytes Pelareorep
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.53 |
| 52 Week Low | 1.25 |
| Average Volume | 7,769,969 |
| 200-Day Moving Average | 3.68 |
| 50-Day Moving Average | 5.86 |
| 20-Day Moving Average | 6.60 |
| 10-Day Moving Average | 8.01 |
| Average True Range | 1.04 |
| RSI (14) | 57.81 |
| ADX | 32.31 |
| +DI | 33.22 |
| -DI | 16.38 |
| Chandelier Exit (Long, 3 ATRs) | 7.41 |
| Chandelier Exit (Short, 3 ATRs) | 7.85 |
| Upper Bollinger Bands | 9.86 |
| Lower Bollinger Band | 3.35 |
| Percent B (%b) | 0.7 |
| BandWidth | 98.67 |
| MACD Line | 0.82 |
| MACD Signal Line | 0.66 |
| MACD Histogram | 0.1636 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 8.62 | ||||
| Resistance 3 (R3) | 8.61 | 8.38 | 8.50 | ||
| Resistance 2 (R2) | 8.38 | 8.20 | 8.38 | 8.46 | |
| Resistance 1 (R1) | 8.15 | 8.09 | 8.03 | 8.15 | 8.42 |
| Pivot Point | 7.91 | 7.91 | 7.85 | 7.91 | 7.91 |
| Support 1 (S1) | 7.68 | 7.73 | 7.57 | 7.69 | 7.42 |
| Support 2 (S2) | 7.45 | 7.62 | 7.45 | 7.38 | |
| Support 3 (S3) | 7.22 | 7.45 | 7.34 | ||
| Support 4 (S4) | 7.22 |
